’19 NOVEL AUTOPHAGY-TARGETING CHIMERA (AUTOTAC) COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING,
OR TREATING DISEASES THROUGH TARGET PROTEIN DEGRADATION COMPRISING SAME (KR, US, EP, JP, CN, AU, IN, IL, TW)
The present invention relates to: an autophagy-targeting chimera (AUTOTAC) compound in which a novel p62 ligand and
a target-binding ligand are linked by means of a linker, or a stereoisomer, solvate, hydrate, or prodrug of the AUTOTAC compound;
and a pharmaceutical or food composition for preventing or treating diseases through target protein degradation comprising same as an active ingredient.
The present invention not only allows a concentration adjustment with a specific protein targeted,
but also allows delivery of drugs and other low molecular weight compounds to lysosomes.
The AUTOTAC compound according to the present invention selectively removes specific proteins and
thus can be usefully employed as a pharmaceutical composition for preventing, alleviating, or treating various diseases.